FDA Regulation of Research Peptides: What Researchers Need to Know

# FDA Regulation of Research Peptides: What Researchers Need to Know

For Research Purposes Only — Not Intended for Human or Animal Consumption

Introduction

The regulatory landscape for research peptides in the United States is complex and frequently misunderstood. This article provides a factual overview of the FDA regulatory framework as it applies to peptide research chemicals, based on publicly available regulatory guidance and law.

Important disclaimer: This article is for informational purposes only and does not constitute legal advice. Researchers should consult qualified legal counsel for guidance specific to their situation.

The Drug Definition and Research Chemicals

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a "drug" is defined as any article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or function of the body.

The critical word is "intended." A chemical compound is regulated as a drug based on its intended use, not its chemical structure alone. A compound sold with claims of therapeutic benefit or intended for human consumption is regulated as a drug; the same compound sold for legitimate laboratory research purposes occupies a different regulatory space.

Research chemicals — compounds sold for in vitro laboratory research or animal research — are not drugs under the FD&C Act when sold for legitimate research purposes without therapeutic claims. However, this distinction requires that:

1. The compound is not sold with claims of therapeutic benefit
2. The compound is not intended for human consumption
3. The compound is not marketed in a way that implies human use

The 503A/503B Compounding Framework

A separate regulatory framework governs compounding pharmacies that prepare peptide medications for patient use. Under Section 503A of the FD&C Act, licensed pharmacies can compound medications for individual patients based on a valid prescription, using bulk drug substances that appear on the FDA's approved bulk drug substances list.

The FDA has taken enforcement action against compounding pharmacies that compound peptides not on the approved bulk drug substances list. In 2023-2024, the FDA issued guidance and enforcement actions regarding the compounding of semaglutide, tirzepatide, and other GLP-1 receptor agonists, as well as various peptides including BPC-157 and TB-500.

Importantly, the 503A/503B framework applies to compounding pharmacies, not to research chemical suppliers. Research chemical suppliers operate under a different regulatory framework focused on legitimate research use.

The Research Use Exemption

The FDA recognizes that legitimate scientific research requires access to compounds that have not been approved as drugs. Researchers at universities, pharmaceutical companies, and research institutions routinely work with unapproved compounds in the course of drug discovery and basic science research.

For legitimate research use, the key requirements are: - The compound is used in a controlled laboratory setting - The research is conducted by qualified researchers - The compound is not administered to humans outside of an approved clinical trial - The research is not commercial in nature (i.e., not selling the compound for human use)

Importation Considerations

The importation of research chemicals is subject to both FDA and Customs and Border Protection (CBP) oversight. The FDA has authority to detain or refuse entry to imported articles that appear to be unapproved drugs or that violate the FD&C Act.

Research chemicals imported for legitimate laboratory use are generally not subject to the same scrutiny as pharmaceutical drugs, but importers should be prepared to document the legitimate research purpose of any imported compounds.

The Evolving Regulatory Landscape

The regulatory landscape for research peptides has been evolving. The FDA has increased enforcement attention on peptides that are widely used in ways that suggest human consumption rather than laboratory research. Suppliers and researchers should monitor FDA guidance documents and enforcement actions for updates to the regulatory framework.

The 2023 FDA guidance on bulk drug substances for compounding, and subsequent enforcement actions, represent a significant development in the regulatory treatment of peptides. Researchers should be aware of these developments and their potential implications for research supply chains.

Practical Guidance for Researchers

1. Document research purpose: Maintain clear documentation of the legitimate research purpose for any peptide compounds
2. Avoid therapeutic claims: Do not make or accept claims of therapeutic benefit for research compounds
3. Use appropriate institutional channels: University researchers should work through their institution's procurement and compliance systems
4. Stay current on regulatory developments: The regulatory landscape is evolving; monitor FDA guidance documents

References

1. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321(g)(1).
2. FDA. (2023). Guidance for Industry: Compounding Under Sections 503A and 503B of the FD&C Act.
3. FDA. (2024). Bulk Drug Substances That May Be Used in Compounding Under Section 503A of the FD&C Act.